Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462920 | 0.96 | MET (0.72) | METMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12463577 | 0.96 | MET (0.71) | MET | |
| SCHEMBL12462929 | 0.93 | MET (0.72) | METMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12462925 | 0.93 | MET (0.72) | METMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12463183 | 0.92 | MET (0.71) | METMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12462941 | 0.92 | MET (0.71) | METMAPTSMN1; SMN2 | |
| SCHEMBL12462939 | 0.91 | MET (0.70) | MET | |
| SCHEMBL12462936 | 0.91 | MET (0.70) | MET | |
| SCHEMBL12463184 | 0.91 | MET (0.77) | MET | |
| SCHEMBL12463197 | 0.91 | MET (0.69) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-2152370-B1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-07-06 | — | — | EP | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
| WO-2008145242-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885MAPT 4161/4885SMN1; SMN2 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.